ClinicalTrials.gg
CompletedNCT00446433Updated Dec 1, 2016

A Study to Evaluate CC-5013 in the Treatment of Adolescents and Adults With Moderately Severe Crohn's Disease

A Phase 2 interventional study of CC-5013 in Crohn's Disease, sponsored by Celgene Corporation. Completed at 20 sites in 4 countries. Open to participants aged 12 Years to 75 Years. Per ClinicalTrials.gov, last updated 2016-12-01.

Sponsored by Celgene Corporation (part of Bristol-Myers Squibb) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
12 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies in Crohn Disease by Bristol-Myers Squibb — none open to participants now, none under way, none of them phase 3. Crohn Disease · Bristol-Myers Squibb.

Enrollment
10th of 16
90 · median 180
Started
2002
the only one that year
Phase 2
6 of 16
none open now
Registered
2nd of 16
by date

Among the 16 studies in Crohn Disease by Bristol-Myers Squibb, this one is the 10th largest by enrollment, is the only one that started in 2002, is one of 6 in phase 2, and was the 2nd registered.

Crohn Disease

1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

None of the 16 studies in Crohn Disease by Bristol-Myers Squibb is open now. The open studies under Crohn Disease, anywhere →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.

This study: 12 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 16 studies in Crohn Disease by Bristol-Myers Squibb as a file.
02

Study summary

A Multicenter, Randomized, Double-Blind, Placebo-Controlled,Parallel-Group Study to Evaluate the Safety and Efficacy of CC-5013 in the Treatment of Adolescents and Adults with Moderately Severe Crohn's Disease

03

Conditions studied

  • Crohn's Disease

Browse trials for

04

Who can participate

Ages eligible
12 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female subjects > 12 and \< 75 years of age.
  2. Adolescent and adult female subjects must be of non- (hysterectomy) or be using one highly effective method (e.g., IUD, hormonal , tubal ligation) of birth control during the entire study. Abstinence will be considered an acceptable method of birth control for adolescent females aged 12-17 years who are not sexually active and who the investigator feels will be compliant with this requirement for the 12-week treatment period. Female subjects who are must have had 24 continuous months of amenorrhea.
  3. Negative pregnancy test for females of child bearing potential.
  4. A history of Crohn's Disease (CD) of greater than 1-year duration diagnosed and documented by standard clinical, radiographic, endoscopic, histopathological criteria.
  5. Signs and symptoms of moderately severe CD as defined by a Crohn's Disease Activity Index (CDAI) score of > 220 and \< 400.
  6. Normal thyroid function as documented by normal TSH (thyroid stimulating hormone).
  7. The subject's treatment for CD must be unchanged, as described below:

    The start date of the medications listed below must be at least 4 weeks prior to randomization, and the dose must have been unchanged for at least 2 weeks prior to that visit. Medication doses may be decreased but not increased throughout the study. If not currently using these agents, the stop date of any previous treatment with these agents must be at least 4 weeks prior to randomization. The medications are:

    • oral or systemic
    • metronidazole (Flagyl®)
    • sulfasalazine
    • oral mesalamine
    • oral olsalazine
    • topical rectal therapy with corticosteroids or mesalamine
  8. The start date of the medications listed below must be at least 3 months (12 weeks) prior to randomization, and the dose must have been unchanged for at least 4 weeks. Medication doses may be decreased but not increased throughout the study. If not currently using these agents, the stop date of any previous treatment with these agents must be at least 6 weeks prior to randomization. The medications are:

    • azathioprine (AZA)
    • 6-mercaptopurine (6 MP)
    • methotrexate
  9. Subject's screening laboratory test results must meet the following criteria:

    • > 8.5 g/dL.
    • white blood cells (WBC) > 3.5 x 109 / L.
    • neutrophils > 1.5 x 109/L and lymphocytes >0.5 x 109/L.
    • > 100 x 109 / L.
    • , (ALT), aspartate transaminase (AST) , and alkaline phosphate levels must not be above two times the .
    • serum albumin > 3.2 mg /dL for adults (18-75) and serum albumin > 2.8 mg/dL for adolescents between the ages of 12-17.
    • serum creatinine \< 2.0 mg/dL
  10. Subjects must be able to adhere to the study visit schedule and other protocol requirements.
  11. The subject must understand and voluntarily sign an document. Adolescent subjects under 18 years of age must have parent/guardian consent as evidenced by a signature on the consent form as well as their own assent, as evidenced by signature on the consent form.
  12. The subject must be at least 25 kg (55 lbs).

Exclusion criteria

Exclusion Criteria:

  1. Pregnancy or lactation.
  2. Predisposition to cardiac arrhythmias and history of cardiac disease.
  3. Diagnosis of ulcerative colitis.
  4. CD that is limited to the stomach and proximal small intestine.
  5. Known severe fixed symptomatic stenosis or stricture of the small or large intestine.
  6. Current evidence of bowel obstruction, or history within the 3 months preceding randomization confirmed with objective radiographic or endoscopic evidence of a stricture with resulting obstruction (dilation of the bowel proximal to the stricture observed upon barium enema or an inability to traverse the stricture at endoscopy.
  7. Subjects who have undergone a proctocolectomy or total colectomy with ileorectal anastomosis; segmental colectomy is permitted.
  8. Colostomy or ileostomy.
  9. Subjects with fulminant disease requiring parenteral treatment, hospitalization, or felt to be in imminent need of surgery, i.e. toxic megacolon, active gastrointestinal bleeding, history of significant ulcer disease and/or esophagitis, peritonitis, intestinal obstruction, perforation, or intra-abdominal abscess requiring surgical drainage.
  10. Subjects requiring intravenous nutritional support with total parenteral nutrition (TPN)/partial parenteral nutrition (PPN) that provides > 50 % of total daily caloric intake.
  11. Subjects in whom enteral nutrition with elemental or semi-elemental formula comprises more than 50% of their total daily caloric intake. For adolescents between the ages of 12-17, subjects in whom enternal nutrition with elemental or semi-elemental formula comprises more the 75% of their total daily caloric intake.
  12. Current signs or symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, endocrine (including thyroid as documented by an abnormal TSH), pulmonary, cardiac, neurological, or cerebral disease, including the following specific exclusions: uncontrolled diabetes, unstable ischemic heart disease, uncontrolled or recent seizures, diseases not related to inflammatory bowel diseases, chronic respiratory insufficiency, or recent cerebral vascular accident (within 2 months of randomization).
  13. Serious infections or history of opportunistic infections; less serious infections within 3 months of randomization, such as acute upper respiratory tract infections (colds) or uncomplicated urinary tract infection are permitted at the discretion of the Investigator. The following are specific exclusions:

    • Chronic and C
    • Documented infection, ARC (AIDS related complex), AIDS, or immune deficiency.
  14. Stool examination positive for enteric pathogens (including Clostridium difficile),pathogenic ova, or parasites.
  15. Concomitant or recent medication use as follows:

    • Treatment with any other therapeutic agent targeted at reducing TNF-a, e.g., CC-1088, thalidomide, cyclosporine, or pentoxifylline within 4 weeks of randomization, and mycophenolate (Cellcept), infliximab (Remicadeä), Enbrelä, or FK506 (Tacrolimus) within 8 weeks of randomization
    • Treatment with interleukin-2 or -10 or other immunomodifier agent within 24 weeks of randomization.
    • Requirement of systemic corticosteroid therapy for other disease(s), e.g., asthma. Inhaled steroids for treating asthma are acceptable for this protocol.
    • Subjects receiving anticoagulant therapy (other than a total daily aspirin dose of 325 mg or less).
    • Subjects having received non CD-directed antibiotic therapy within 2 weeks of randomization. CD-directed antibiotic therapy, for example with ciprofloxacin or metronidazole, is acceptable provided the dose has been stable for the 2 weeks prior to randomization.
    • Subjects who have received an drug within 30 days of randomization.
  16. Subjects with a history of , except basal cell or squamous cell carcinoma of the skin or cervical carcinoma in situ.
  17. Dysplasia (low-grade or high-grade) of the colon/small bowel within the last 5 years prior to screening.
  18. Subjects who, in the judgment of the Investigator, are unwilling or unable to comply with all the protocol-related assessments and procedures, including completion of a daily diary.
  19. History of alcohol or other drug abuse within 1 year of randomization, or any conditions associated with poor compliance.
  20. Subjects in whom multiple venipunctures are not feasible due to poor tolerability or lack of easy access.
  21. Any condition which, in the opinion of the Investigator, places the subject at unacceptable risk if he/she were to participate in the study.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
90 participants

Interventions

06

Study locations

20 sites
  • Advanced Clinical Therapeutics
    Tucson, Arizona 85712, United States
  • Advanced Clinical Research Institute
    Anaheim, California 92801, United States
  • Washington Hospital Center Physicians Office Building
    Washington D.C., District of Columbia 20010, United States
  • Springfield Clinic
    Springfield, Illinois 62794-9248, United States
  • Wake Research Associates
    Raleigh, North Carolina 27612, United States
  • Hopital Saint Louis
    Paris, 75010, France
  • Rambam Hospital
    Haifa, Israel
  • Department of Medicine A, Liver & Gastroenterology Units
    Jerusalem, 91120, Israel
  • Department of Gastroenterology and Hepatology
    Tel Litwinsky, 52621, Israel
  • Department of Gastroenterology
    Dartford, Kent DA2 8DA, United Kingdom
  • Department of Gastroenterology
    Bristol, BS2 8HW, United Kingdom
  • Addenbrookes Hospital
    Cambridge, CB2 2QQ, United Kingdom
  • Department of Medicine
    Cardiff, CF 14 4XW, United Kingdom
  • Department of Gastroenterology
    London, NW3 2QG, United Kingdom
  • Department of Gastroenterology
    London, W12 0HS, United Kingdom
  • Department of Gastroenterology
    London, W1N 8AA, United Kingdom
  • Department of Gastroenterology
    Manchester, M13 9WL, United Kingdom
  • St. Mark's Hospital
    Middlesex, HA 1 3UI, United Kingdom
  • Department of Gastroentroerology
    Newcastle, NE1 4LP, United Kingdom
  • Nottingham, United Kingdom
07

References and documents

Publications

  • Mansfield JC, Parkes M, Hawthorne AB, Forbes A, Probert CS, Perowne RC, Cooper A, Zeldis JB, Manning DC, Hawkey CJ. A randomized, double-blind, placebo-controlled trial of lenalidomide in the treatment of moderately severe active Crohn's disease. Aliment Pharmacol Ther. 2007 Aug 1;26(3):421-30. doi: 10.1111/j.1365-2036.2007.03385.x. PubMed 17635377 ↗
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2002 and a completion of Dec 2003. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 7, 2007
First posted
Mar 12, 2007
Start
Mar 2002
Completion
Dec 2003
Last update
Dec 1, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
No changes since tracking began. The registry record was last updated on Dec 1, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00446433
Responsible party
Sponsor
First posted
Mar 12, 2007
Start date
Mar 2002
Completion
Dec 2003
Last update
Dec 1, 2016
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lenalidomide

Start the discussion